20(R)-Ginsenoside Rh2 (Synonyms: 20(R)-人参皂苷Rh2)

目录号: HY-N1401 纯度: ≥98.0%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

20(R)-Ginsenoside Rh2 是一种口服有效的、具备多种生物活性的原人参二醇型皂苷。20(R)-Ginsenoside Rh2 通过诱导细胞周期阻滞、促进凋亡 (apoptosis) 对非小细胞肺癌、肝癌具有显著抑制作用。20(R)-Ginsenoside Rh2 能通过抑制病毒 DNA 复制发挥抗 γ-疱疹病毒作用。20(R)-Ginsenoside Rh2 降低一氧化氮 (NO) 、前列腺素 E2 (PGE2) 和活性氧 (ROS) 水平抑制炎症介质，通过减少 ROS 和抑制 MMP-9/2，可延缓皮肤光老化。20(R)-Ginsenoside Rh2通过激活 Akt1/PKB 信号通路，加速肌肉损伤后的恢复。20(R)-Ginsenoside Rh2可抑制破骨细胞形成发挥抗骨质疏松作用。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

20(R)-Ginsenoside Rh2 Chemical Structure

CAS No. : 112246-15-8

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥500	In-stock
5 mg	￥1000	In-stock
10 mg	￥1400	In-stock
25 mg	￥2240	In-stock
50 mg	￥3136	In-stock
100 mg	￥4390	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of 20(R)-Ginsenoside Rh2:

20(R)-Ginsenoside Rh2 (Standard) 询价

MCE 顾客使用本产品发表的 1 篇科研文献

•Sci Adv. 2023 Jan 20;9(3):eadd3867. [Abstract]

20(R)-Ginsenoside Rh2 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 MMP 亚型特异性产品:

查看所有亚型

MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

查看 HSV 亚型特异性产品:

查看所有亚型

HSV-1 HSV-2 HSV

查看 NO Synthase 亚型特异性产品:

查看所有亚型

nNOS iNOS eNOS

查看 Prostaglandin Receptor 亚型特异性产品:

查看所有亚型

DP EP FP IP TXA₂/TP TXB₂

查看 Akt 亚型特异性产品:

查看所有亚型

Akt Akt1 Akt2 Akt3

生物活性
纯度 & 产品资料
参考文献

生物活性

20(R)-Ginsenoside Rh2 is an orally active protopanaxadiol-type saponin with multiple biological activities. 20(R)-Ginsenoside Rh2 exerts a significant inhibitory effect on non-small cell lung cancer and liver cancer by inducing cell cycle arrest and promoting apoptosis. 20(R)-Ginsenoside Rh2 exerts anti-γ-herpesvirus effects by inhibiting viral DNA replication. 20(R)-Ginsenoside Rh2 inhibits inflammatory mediators by reducing the levels of NO, PGE2, and ROS; it can delay skin photoaging by reducing ROS and inhibiting MMP-9/2 activity. 20(R)-Ginsenoside Rh2 accelerates the recovery after muscle injury by activating the Akt1/PKB signaling pathway. 20(R)-Ginsenoside Rh2 can inhibit osteoclast formation and exert an anti-osteoporosis effect^[1]^[2]^[3]^[4]^[5]^[6].

IC₅₀ & Target^[1]^[5]

MMP9

MMP2

Akt1

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
DU-145	IC₅₀	38 μM Compound: Rh2	Antiproliferative activity against human DU-145 cells incubated for 3 days Antiproliferative activity against human DU-145 cells incubated for 3 days	[PMID: 32702586]
HCT-116	IC₅₀	19.6 μM Compound: Rh2	Cytotoxicity against human HCT-116 assessed as reduction in cell viability by MTT assay Cytotoxicity against human HCT-116 assessed as reduction in cell viability by MTT assay	[PMID: 32702586]
HCT-116	IC₅₀	35 μM Compound: Rh2	Induction of cell death in human HCT-116 cells incubated for 48 hrs by trypan blue staining based analysis Induction of cell death in human HCT-116 cells incubated for 48 hrs by trypan blue staining based analysis	[PMID: 32702586]
HeLa	IC₅₀	2.52 μg/mL Compound: Rh2	Induction of apoptosis in human HeLa cells incubated for 2 hrs by fluorescence microscopic analysis Induction of apoptosis in human HeLa cells incubated for 2 hrs by fluorescence microscopic analysis	[PMID: 32702586]
HepG2	IC₅₀	1.648 μg/mL Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 72 hrs Induction of apoptosis in human HepG2 cells incubated for 72 hrs	[PMID: 32702586]
HepG2	IC₅₀	100 μM Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 48 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 cells incubated for 48 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HepG2	IC₅₀	129.2 μM Compound: Rh2	Induction of apoptosis in human HepG2 beta-catenin cells incubated for 48 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 beta-catenin cells incubated for 48 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HepG2	IC₅₀	42.12 μM Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 24 hrs Induction of apoptosis in human HepG2 cells incubated for 24 hrs	[PMID: 32702586]
HepG2	IC₅₀	58.12 μM Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 72 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 cells incubated for 72 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HepG2	IC₅₀	83.33 μM Compound: Rh2	Induction of apoptosis in human HepG2 beta-catenin cells incubated for 72 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 beta-catenin cells incubated for 72 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HL-60	IC₅₀	25.59 μM Compound: Rh2	Induction of apoptosis in human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of apoptosis in human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 32702586]
HL-60	IC₅₀	38 μM Compound: Rh2	Cytotoxicity against human HL-60 cells measured after 24 hrs by MTT assay Cytotoxicity against human HL-60 cells measured after 24 hrs by MTT assay	[PMID: 32702586]
Jurkat	IC₅₀	35 μM Compound: Rh2	Inhibition of proliferation in human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Inhibition of proliferation in human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 32702586]
K562	IC₅₀	60 μM Compound: Rh2	Cytotoxicity against human K562 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human K562 cells incubated for 48 hrs by CCK-8 assay	[PMID: 32702586]
Kasumi 1	IC₅₀	60.06 μM Compound: Rh2	Induction of apoptosis in human Kasumi 1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of apoptosis in human Kasumi 1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 32702586]
KG-1	IC₅₀	60 μM Compound: Rh2	Cytotoxicity against human KG-1 alpha cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human KG-1 alpha cells incubated for 48 hrs by CCK-8 assay	[PMID: 32702586]
LNCaP	IC₅₀	17 μM Compound: Rh2	Antiproliferative activity against human LNCaP cells incubated for 3 days Antiproliferative activity against human LNCaP cells incubated for 3 days	[PMID: 32702586]
PC-3	IC₅₀	35 μM Compound: Rh2	Antiproliferative activity against human PC-3 cells incubated for 3 days Antiproliferative activity against human PC-3 cells incubated for 3 days	[PMID: 32702586]
SK-HEP1	IC₅₀	3.15 μg/mL Compound: Rh2	Induction of apoptosis in human SK-HEP1 cells incubated for 2 hrs by fluorescence microscopic analysis Induction of apoptosis in human SK-HEP1 cells incubated for 2 hrs by fluorescence microscopic analysis	[PMID: 32702586]
SW480	IC₅₀	35 μM Compound: Rh2	Induction of cell death in human SW480 cells incubated for 48 hrs by trypan blue staining based analysis Induction of cell death in human SW480 cells incubated for 48 hrs by trypan blue staining based analysis	[PMID: 32702586]
SW480	IC₅₀	4.06 μg/mL Compound: Rh2	Induction of apoptosis in human SW480 cells incubated for 2 hrs by fluorescence microscopic analysis Induction of apoptosis in human SW480 cells incubated for 2 hrs by fluorescence microscopic analysis	[PMID: 32702586]
U-937	IC₅₀	38 μM Compound: Rh2	Cytotoxicity against human U-937 cells measured after 24 hrs by MTT assay Cytotoxicity against human U-937 cells measured after 24 hrs by MTT assay	[PMID: 32702586]

体外研究
(In Vitro)

20(R)-Ginsenoside Rh2 (0-50 μM, 24 h) 能够抑制 NO、PGE2、ROS 和 MMP-9 (基质金属蛋白酶-9) 的产生，但不能调节由 LPS (HY-D1056) 在 RAW264.7 巨噬细胞中诱导的 MMP-2 (基质金属蛋白酶-2) 的明胶酶活性^[1]。
20(R)-Ginsenoside Rh2 (0-25 μM, 24 h) 降低 ROS 水平 (但不能调节 NO)，抑制未受刺激的 HaCat 细胞中 MMP-9 和 MMP-2 的明胶酶活性，且对 HaCat 细胞无细胞毒性^[1]。
20(R)-Ginsenoside Rh2 (0-200 μg/mL, 24 h-28 d) 抑制 95D 和 NCI-H460 细胞的增殖和集落形成，并诱导这两种细胞凋亡^[3]。
20(R)-Ginsenoside Rh2 (50-100 μg/mL, 48 h) 介导 95D 细胞的 G1/S 期细胞周期阻滞和 NCI-H460 细胞的 G2 期细胞周期阻滞^[3]。
20(R)-Ginsenoside Rh2 (0-100 μM, 72 h) 通过抑制 MHV-68 进入 NIH-3T3 细胞后的复制，显著抑制小鼠 γ 疱疹病毒68 (MHV-68) 的增殖 (IC₅₀ = 2.77 μM)，且抑制人 γ 疱疹病毒 (KSHV) 阳性细胞系 BC3 的裂解复制^[4]。
20(R)-Ginsenoside Rh2 (5-10 μg/mL, 72 h) 通过激活 Akt/PKB 信号通路并抑制 p27^Kip1 和 p57^KIP2 的表达，增加 C2C12 小鼠成肌细胞的增殖并抑制原代大鼠心肌细胞的增殖^[5]。
20(R)-Ginsenoside Rh2 对破骨细胞形成有抑制作用 (IC₅₀ = 12 μM)，对破骨细胞增殖无抑制作用^[6]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	HaCat cells
Concentration:	0, 0.2, 1, 5 and 25 μM
Incubation Time:	24 h
Result:	Observed the reduction of MMP-9 and MMP-2 gelatinolytic activity. Inhibited TNF-a-induced MMP-9 gelatinolytic activity.

Cell Proliferation Assay^[3]

Cell Line:	95D and NCI-H460 cells
Concentration:	0, 50, 100, 200 µg/mL
Incubation Time:	24, 48 and 72 h
Result:	Exhibited the IC₅₀s of 1006.15, 491.46 and 596.81 µg/mL at 24, 48 and 72 h against 95D cells. Exhibited the IC₅₀s of 386,77, 783,49 and 368,32 µg/mL at 24, 48 and 72 h against NCI-H460 cells.

Cell Cycle Analysis^[3]

Cell Line:	95D and NCI-H460 cells
Concentration:	50 and 100 µg/mL
Incubation Time:	48 h
Result:	The accumulation rate of 95D cells in S phase increased from 34.70% to 43.05% and that of NCI‑H460 cells in S phase is 3.64% to 22.94% at 100 µg/mL.

Apoptosis Analysis^[3]

Cell Line:	95D and NCI-H460 cells
Concentration:	50 and 100 µg/mL
Incubation Time:	48 h
Result:	Had the maximum total apoptosis rate of 21.67% in 95D cells and NCI‑H460 cells total apoptosis rate was 27.30%. The number of nuclear fragmentation (apoptotic bodies) has significantly increased.

RT-PCR^[4]

Cell Line:	NIH-3T3 cells infected MHV-68
Concentration:	100 µM
Incubation Time:	72 h
Result:	Reduced the mRNA expression of the viral lysate gene RTA. Reduced the expression of the RTA (key gene during the lytic phase) and ORF56 (gene related to DNA synthesis).

Western Blot Analysis^[4]

Cell Line:	NIH-3T3 cells infected MHV-68
Concentration:	100 µM
Incubation Time:	72 h
Result:	Significantly decreased the expression of the late viral protein ORF45 (capsid protein) and M9.

Immunofluorescence^[5]

Cell Line:	C2C12 murine myoblasts
Concentration:	5 and 10 µg/mL
Incubation Time:	72 h
Result:	Selectively enhanced of myoblast proliferation (BrdU of human primary cells increased by 35%). Inhibited the proliferation of cardiac fibroblasts (CdF).

RT-PCR^[5]

Cell Line:	C2C12 myoblast cells and primary rat cardiomyocytes
Concentration:	5 µg/mL
Incubation Time:	72 h
Result:	Significantly downregulated p27^Kip1 and p57^Kip2 mRNA in C2C12 myoblast cells. Downregulated p27^Kip1 and showed no change on p57^Kip2 in primary rat cardiomyocytes.

Western Blot Analysis^[5]

Cell Line:	C2C12 myoblast cells and primary rat cardiomyocytes
Concentration:	5 and 10 µg/mL
Incubation Time:	72 h
Result:	Significantly increased Akt phosphorylation in C2C12 myoblast cells. Consistent with the mRNA results.

体内研究
(In Vivo)

20(R)-Ginsenoside Rh2 (2-6 mg/kg, p.o., 每日一次共 10 天) 通过下调 Bcl-2 诱导肿瘤细胞凋亡，在小鼠肝癌模型中发挥了显著的抗肿瘤效果^[2]。
20(R)-Ginsenoside Rh2 (2 mg/kg, i.p., 每日一次共 7 天) 可促进心肌梗死大鼠模型中心肌细胞的增殖并改善心脏功能^[5]。
20(R)-Ginsenoside Rh2 (2 mg/kg, i.p., 每日一次共 7-14 天) 可加速骨骼肌退化小鼠模型中骨骼肌的再生并减少纤维化^[5]。
20(R)-Ginsenoside Rh2 (5 μg/mL) 可增强斑马鱼心肌细胞的增殖^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Myocardial infarction model established in adult male 8-week-old Sprague Dawley rats (weight range 230-250 g)^[5]
Dosage:	2 mg/kg
Administration:	Intraperitoneal injection (i.p.), once daily, for 7 days
Result:	Increased ejection fraction (EF) by 28%, left ventricular wall thickness increased, and scar area decreased.

Animal Model:	Hepatoma model established in female H22 hepatoma-bearing mice (18-22g)^[2]
Dosage:	2, 3, 4, 6mg/kg
Administration:	Oral administration (p.o.), once daily for 10 days
Result:	Significantly inhibited tumor growth, and the weight of the mice remained stable. The number of nuclear divisions decreased, the area of necrosis increased, and apoptotic-like cells (with nuclear shrinkage and fragmentation) were significantly present. Significantly downregulated the expression of Bcl-2, Bax/Bak/Bcl-xL, but no significant change was observed.

Animal Model:	Skeletal muscle degeneration model established in 8-week-old male C57BL/6 mice (weight range 23-25 g) ^[5]
Dosage:	2 mg/kg
Administration:	Intraperitoneal injection (i.p.), once daily, for 7 and 14 days
Result:	Observed a large number of central nuclear myofibers (indicative of new formation) with their diameters significantly increased compared to the control group during 7 days treatment. The number of inflammatory cells decreased by 50% during 7 days treatment. Arranged more closely in the muscle fibers, reduced the scar area, and the swimming time remained stable during 14 days treatment.

分子量

622.87

Formula

C₃₆H₆₂O₈

CAS 号

112246-15-8

性状

固体

颜色

White to off-white

中文名称

20(R)-人参皂苷Rh2

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 125 mg/mL (200.68 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6055 mL	8.0274 mL	16.0547 mL
5 mM	0.3211 mL	1.6055 mL	3.2109 mL
10 mM	0.1605 mL	0.8027 mL	1.6055 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: ≥98.0%

选择批次：

Data Sheet (643 KB) SDS (252 KB)

COA (288 KB) HNMR (239 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Choi WY, et al. Anti-inflammatory, antioxidative and matrix metalloproteinase inhibitory properties of 20(R)-ginsenoside Rh2 in cultured macrophages and keratinocytes. J Pharm Pharmacol. 2013 Feb;65(2):310-6. [Content Brief]

[2]. Lv Q, et al. Antitumoral Activity of (20R)- and (20S)-Ginsenoside Rh2 on Transplanted Hepatocellular Carcinoma in Mice. Planta Med. 2016 May;82(8):705-11. [Content Brief]

[3]. Liu X, et al. Comparative study on the antitumour activity of 20 (R)-ginsenoside Rh2 and 20 (S)-ginsenoside Rh2 from Panax ginseng against non-small cell lung cancer in vitro[J]. Pharmacognosy Magazine, 2022, 18(80).

[4]. Kim AR, et al. Screening ginseng saponins in progenitor cells identifies 20(R)-ginsenoside Rh2 as an enhancer of skeletal and cardiac muscle regeneration. Sci Rep. 2020 Mar 18;10(1):4967. [Content Brief]

[5]. Kang S, et al. Antiviral activity of 20(R)-ginsenoside Rh2 against murine gammaherpesvirus. J Ginseng Res. 2017 Oct;41(4):496-502. [Content Brief]

[6]. Liu J, et al. 20(R)-ginsenoside Rh2, not 20(S), is a selective osteoclastgenesis inhibitor without any cytotoxicity. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3320-3. [Content Brief]

20(R)-Ginsenoside Rh2 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6055 mL	8.0274 mL	16.0547 mL	40.1368 mL
	5 mM	0.3211 mL	1.6055 mL	3.2109 mL	8.0274 mL
	10 mM	0.1605 mL	0.8027 mL	1.6055 mL	4.0137 mL
	15 mM	0.1070 mL	0.5352 mL	1.0703 mL	2.6758 mL
	20 mM	0.0803 mL	0.4014 mL	0.8027 mL	2.0068 mL
	25 mM	0.0642 mL	0.3211 mL	0.6422 mL	1.6055 mL
	30 mM	0.0535 mL	0.2676 mL	0.5352 mL	1.3379 mL
	40 mM	0.0401 mL	0.2007 mL	0.4014 mL	1.0034 mL
	50 mM	0.0321 mL	0.1605 mL	0.3211 mL	0.8027 mL
	60 mM	0.0268 mL	0.1338 mL	0.2676 mL	0.6689 mL
	80 mM	0.0201 mL	0.1003 mL	0.2007 mL	0.5017 mL
	100 mM	0.0161 mL	0.0803 mL	0.1605 mL	0.4014 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

20(R)-Ginsenoside Rh2 (Synonyms: 20(R)-人参皂苷Rh2)

Customer Review

Other Forms of 20(R)-Ginsenoside Rh2:

MCE 顾客使用本产品发表的 1 篇科研文献

20(R)-Ginsenoside Rh2 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 MMP 亚型特异性产品:

查看 HSV 亚型特异性产品:

查看 NO Synthase 亚型特异性产品:

查看 Prostaglandin Receptor 亚型特异性产品:

查看 Akt 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

20(R)-Ginsenoside Rh2 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

20(R)-Ginsenoside Rh2 (Synonyms: 20(R)-人参皂苷Rh2)

Customer Review

Other Forms of 20(R)-Ginsenoside Rh2:

20(R)-Ginsenoside Rh2 相关抗体

MCE 顾客使用本产品发表的 1 篇科研文献

20(R)-Ginsenoside Rh2 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 MMP 亚型特异性产品:

查看 HSV 亚型特异性产品:

查看 NO Synthase 亚型特异性产品:

查看 Prostaglandin Receptor 亚型特异性产品:

查看 Akt 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

20(R)-Ginsenoside Rh2 相关抗体:

摩尔计算器

稀释计算器

20(R)-Ginsenoside Rh2 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z